Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

Johnson & Johnson JNJ announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

We thank Robert J van Soest and Roderick C N van den Bergh for their Correspondence about the prevention of severe genitourinary events in the PEACE-1 trial. In our trial, we used objective events (eg ...

Sanofi SNY has announced that the FDA has granted a fast-track designation to its one-time intravitreal gene therapy, SAR446597, for the treatment of geographic atrophy (GA) due to age-related ...

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting ...

Detailed price information for Charles River Laboratories Intl (CRL-N) from The Globe and Mail including charting and trades.

– Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to ...

Arvinas' top executive, John Houston, plans to retire after roughly eight years at the helm of the clinical-stage biotechnology company. Arvinas on Wednesday said Houston, who has been president ...